Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colestipol-induced hepatotoxicity.

S M Sirmans1, J K Beck, H L Banh

  • 1Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City 73104, USA.

Pharmacotherapy
|April 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dim nighttime illumination alters photoperiodic responses of hamsters through the intergeniculate leaflet and other photic pathways.

Neuroscience·2011
Same author

Photic and nonphotic seasonal cues differentially engage hypothalamic kisspeptin and RFamide-related peptide mRNA expression in Siberian hamsters.

Journal of neuroendocrinology·2009
Same author

Different neural melatonin-target tissues are critical for encoding and retrieving day length information in Siberian hamsters.

Journal of neuroendocrinology·2007
Same author

Perinatal influences of melatonin on testicular development and photoperiodic memory in Siberian hamsters.

Journal of neuroendocrinology·2005
Same author

Termination of neuroendocrine refractoriness to melatonin in Siberian hamsters (Phodopus sungorus).

Journal of neuroendocrinology·2003
Same author

Testicular and somatic growth in Siberian hamsters depend on the melatonin-free interval between twice daily melatonin signals.

Journal of neuroendocrinology·2002
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

Colestipol, a bile acid-binding resin used for dyslipidemia, can cause asymptomatic liver damage. Discontinuation led to rapid normalization of liver enzymes, highlighting the need for monitoring.

Area of Science:

  • Hepatology
  • Clinical Pharmacology

Background:

  • Bile acid-binding resins, such as colestipol, are frequently prescribed for managing type IIa dyslipidemia.
  • Hepatotoxicity is a rare but potential side effect associated with these lipid-lowering agents.

Observation:

  • A 65-year-old male patient presented with asymptomatic elevated liver enzymes (hepatotoxicity) after three months of colestipol treatment.
  • Transaminase levels were significantly elevated, reaching up to ten times the upper limit of normal.

Findings:

  • Discontinuation of colestipol resulted in a rapid and dramatic decrease in serum transaminases.
  • Liver function tests returned to normal within four weeks of ceasing colestipol therapy.
  • No other causes for hepatocellular injury were identified, and rechallenge was not performed.

Related Experiment Videos

Implications:

  • This case underscores the rare risk of colestipol-induced hepatotoxicity in dyslipidemia patients.
  • Routine liver function test monitoring may be advisable for high-risk individuals undergoing treatment with bile acid-binding resins.
  • Educating patients on potential hepatotoxic side effects is crucial for early detection and management.